T1	Participants 102 128	non-small cell lung cancer
T2	Participants 743 896	Patients were eligible if they had stage I-IIIB NSCLC, unsuitable for curative therapy, or stage IV with a PET-detected extracranial solitary metastasis.
T3	Participants 1290 1327	Eighty-four patients were randomized.